Clozapine in the treatment of refractory psychotic mania.
about
The schizophrenia phenotype in 22q11 deletion syndromeClozapine: Current perspective.Discriminant and concurrent validity of a simplified DSM-based structured diagnostic instrument for the assessment of autism spectrum disorders in youth and young adultsBipolar disorders: new approaches to therapy.The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania.[Anticonvulsants and antipsychotics in the treatment of bipolar disorder].The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyWomen and bipolar disorder across the life spanAtypical antipsychotics and mood stabilization in bipolar disorder.Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.The case for atypical antipsychotics in bipolar disorder.Safety and tolerability of emerging pharmacological treatments for bipolar disorder.Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brainThe role of quetiapine in the treatment of bipolar disorder.Treatment-refractory bipolar disorder: classification to aid in clinical management.Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study.Refractoriness in bipolar disorder: definitions and evidence-based treatment.Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder.Clozapine use reduced psychiatric hospitalization and emergency room visits in patients with bipolar disorder independent of improved treatment regularity in a three-year follow-up period.Gamma activity model for treatment-resistant bipolar psychotic mania.Atypical antipsychotics in the therapy of bipolar disorders: efficacy and safety.A case of clozapine induced acute renal failure.Clozapine-induced cardiotoxicity in rats: Involvement of tumour necrosis factor alpha, NF-κβ and caspase-3.Clozapine Can Be the Good Option in Resistant Mania.Quetiapine in bipolar disorder and cocaine dependence.Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines.The Black Book of Psychotropic Dosing and Monitoring.Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study.Inositol augmentation of lithium or valproate for bipolar depression.Clozapine-Induced Cardiotoxicity: Role of Oxidative Stress, Tumour Necrosis Factor Alpha and NF-κβ.
P2860
Q24633796-7F7A35CB-5244-4D9A-9031-F5FD2CC50EEBQ34021447-4B910E9D-04CE-4562-B38D-3B4A3C4E8061Q34114456-3A491AA8-1791-4EE9-BAFB-27BC499AA23CQ34240963-274592D5-627D-48F8-9B1D-C24BABC5A61BQ34531273-E5A5BED2-ECBF-44A1-86E8-8B32715AA092Q34553398-769E35CE-92A9-4B9C-911B-6A20688552B5Q34606256-5F278F60-03BF-4A97-9597-C0DA8E75207AQ34644698-AACA65B2-A600-4658-9383-AAD49763BE6EQ34676317-861BD307-4BA7-46F5-8905-447A19D47BF8Q35022930-88A48580-EF50-4EE9-883D-949F4ECE48F4Q35073763-FEFEA3C9-1A0E-4873-9EF7-42CF9CD84CBAQ35142739-F21A825B-D249-4F24-A5F8-A0C8CE1A60FEQ35775218-F85199CB-0790-494D-B5AB-039154E94FE8Q36199036-43472DF4-7807-43D3-A566-5296ABB14529Q36338174-81599278-8CF9-4F42-9B73-826DAB9DDDD4Q36458469-5D9EB957-7B6B-49DD-9DD3-372C6A35DBF0Q37552934-77698A11-3D33-40EC-985B-26C525427144Q37613752-ECEF7C9C-5260-454A-8330-6B751765EC7BQ37954423-89EFE0A1-860F-4BC4-A421-79ECCE939956Q38003196-CEA247C0-1C23-406D-BEB7-E524DB909EDBQ38258128-3375967D-F6AD-47BB-A87C-78C5662AB0D6Q39258087-07EE0742-0B5C-4DA6-A6DA-4191841283BBQ40644004-EECDD80A-AA45-442C-8AEC-63C54520054DQ41513240-9527C89C-E4F2-415E-881B-C01FA93EDACEQ41680817-7979F6ED-8AD4-4FD0-AF94-F363338DC1EBQ42375877-CA7C03AC-CE47-4710-AFBD-89EAE96FE63CQ42692308-164E9F5F-5FD3-4E91-81F2-15913E979828Q44259205-C8606DB0-D8B9-4E7A-94E4-9C2EF60E72FEQ46561794-D06374E9-38A0-48BE-93DD-740A42248178Q47642128-C38D0740-AE8E-492F-93A0-A2E02002A049Q50779681-629595A3-3E0C-4D4A-B198-A5B6991BB3FBQ51920292-3D10C4BB-F110-450A-93C2-80F65896101DQ53813714-D7ADB55E-44C5-4E59-9FC6-3F254B4391FD
P2860
Clozapine in the treatment of refractory psychotic mania.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Clozapine in the treatment of refractory psychotic mania.
@en
Clozapine in the treatment of refractory psychotic mania.
@nl
type
label
Clozapine in the treatment of refractory psychotic mania.
@en
Clozapine in the treatment of refractory psychotic mania.
@nl
prefLabel
Clozapine in the treatment of refractory psychotic mania.
@en
Clozapine in the treatment of refractory psychotic mania.
@nl
P2093
P1476
Clozapine in the treatment of refractory psychotic mania.
@en
P2093
P304
P356
10.1176/APPI.AJP.157.6.982
P407
P577
2000-06-01T00:00:00Z